tetano
Editor, Senior Moderator
J Clin Neuromuscul Dis
. 2021 Sep 1;23(1):24-30.
doi: 10.1097/CND.0000000000000367.
Mononeuropathy Multiplex After COVID-19
Nathan Carberry[SUP] 1 [/SUP], Helen Badu[SUP] 1 [/SUP], Christina M Ulane[SUP] 1 [/SUP], Akinpelumi Beckley[SUP] 2 [/SUP], Samuel J Rosenberg[SUP] 2 [/SUP], Keith Brenner[SUP] 3 4 [/SUP], Thomas H Brannagan 3rd[SUP] 1 [/SUP]
Affiliations
Abstract
Objectives: COVID-19 is a novel coronavirus that emerged in 2019 and is responsible for a global pandemic. Numerous neurologic manifestations have been described in the literature regarding COVID-19, but most studies are focused on the central nervous system. The authors have noted an association between prior COVID-19 infection and the development of a systemic neuropathy that manifests with asymmetric sensorimotor loss in the peripheral nervous system. We describe 4 cases of mononeuropathy multiplex that were diagnosed after COVID-19 infection.
Methods: All patients included were treated for severe COVID-19 infection at New York Presbyterian Hospital and subsequently referred to the Columbia Peripheral Neuropathy Center for persistent neuropathy.
Results: Patient history, COVID-19 disease course, and mononeuropathy multiplex diagnostic evaluation of the 4 patients are recounted.
Conclusions: We postulate a connection between COVID-19 and the development of mononeuropathy multiplex with implications in prognostication, rehabilitation strategies, and future treatments.
. 2021 Sep 1;23(1):24-30.
doi: 10.1097/CND.0000000000000367.
Mononeuropathy Multiplex After COVID-19
Nathan Carberry[SUP] 1 [/SUP], Helen Badu[SUP] 1 [/SUP], Christina M Ulane[SUP] 1 [/SUP], Akinpelumi Beckley[SUP] 2 [/SUP], Samuel J Rosenberg[SUP] 2 [/SUP], Keith Brenner[SUP] 3 4 [/SUP], Thomas H Brannagan 3rd[SUP] 1 [/SUP]
Affiliations
- PMID: 34431798
- DOI: 10.1097/CND.0000000000000367
Abstract
Objectives: COVID-19 is a novel coronavirus that emerged in 2019 and is responsible for a global pandemic. Numerous neurologic manifestations have been described in the literature regarding COVID-19, but most studies are focused on the central nervous system. The authors have noted an association between prior COVID-19 infection and the development of a systemic neuropathy that manifests with asymmetric sensorimotor loss in the peripheral nervous system. We describe 4 cases of mononeuropathy multiplex that were diagnosed after COVID-19 infection.
Methods: All patients included were treated for severe COVID-19 infection at New York Presbyterian Hospital and subsequently referred to the Columbia Peripheral Neuropathy Center for persistent neuropathy.
Results: Patient history, COVID-19 disease course, and mononeuropathy multiplex diagnostic evaluation of the 4 patients are recounted.
Conclusions: We postulate a connection between COVID-19 and the development of mononeuropathy multiplex with implications in prognostication, rehabilitation strategies, and future treatments.